In response to a counterfeit drug market that put desperate patients at risk, India’s Ministry of Health and Family Welfare has issued a national mandate requiring tracing across all cancer medications sold in the country. Drug manufacturers and importers now face a deadline of July 2027 to add QR codes or barcodes on packaging, allowing the medicine’s path to be tracked from factory to patient.
Closing the Gaps in the Global Oncology Supply Chain
The regulatory overhaul arrives following the joint Cancer Calculus investigation by The Indian Express and the International Consortium of Investigative Journalists (ICIJ). That collaborative reporting exposed how counterfeiters exploited the costs of oncology drugs. At the center of the crisis sat Keytruda, which commands a market price of 150,000 rupees—more than $1,500 USD—for a single 100-milligram vial in a nation where such sums are unaffordable for most families.
The financial barrier created an opening for illicit operators. In 2024, police in New Delhi arrested 12 men for allegedly stealing empty Keytruda vials from hospitals and pharmacies. The men then allegedly refilled the packaging with antifungal medicine and sold the spurious medicines to cancer patients at a fraction of the cost of authentic Keytruda. According to findings published by the International Consortium of Investigative Journalists, the counterfeit ring’s reach extended beyond India’s borders, including a Nepalese woman who purchased medicine from one of the accused defendants.
How the New Serialization Mandate Works
Under the updated regulatory framework confirmed to The Indian Express, the tracing requirement applies to both drugs manufactured in India and those imported into the country. Whether a vial is manufactured in India or imported, it must carry a QR code or barcode by July 2027. This digital fingerprint will show the medicine’s path from factory to patient.
For a pharmaceutical market vulnerable to counterfeits, the shift toward traceability introduces friction for counterfeiters. By scanning the mandated QR codes or barcodes, the medicine’s path can be traced. This technical safeguard aims to curb the spread of counterfeits, such as the recycling of genuine packaging to mask fraudulent contents exposed by the New Delhi raids.
The Ongoing Battle Over Access and Affordability
While the new tracing mandates target criminal exploitation, investigative findings from the Cancer Calculus series detailed how Merck turned Keytruda into a blockbuster while pricing out cancer patients worldwide, forcing patients into grueling legal battles for the lifesaving drug. When lifesaving care becomes unaffordable, the black market steps in to fill the void.
As India’s July 2027 deadline approaches, the pharmaceutical sector faces a transition to upgrade packaging. Regulators hope that digital tracking will help curb the distribution of counterfeit medicines. What are your thoughts on how regulatory bodies can better balance high drug costs with patient safety? Let’s discuss in the comments below.
Related reading
